Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer

Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast

(2015) Mu-Min Shao et al.   HISTOPATHOLOGY

Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer

(2014) Hee Jin Lee et al.   BREAST CANCER RESEARCH AND TREATMENT

High EGFR gene copy number predicts poor outcome in triple-negative breast cancer

(2014) Heae Surng Park et al.   MODERN PATHOLOGY

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab

(2013) W. J. Gradishar   ANNALS OF ONCOLOGY

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer

(2013) Alessandra Fabi et al.   EXPERT OPINION ON PHARMACOTHERAPY

EGFRGene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast

(2013) Won Hwangbo et al.   Korean Journal of Pathology

Role of epidermal growth factor receptor in breast cancer

(2012) Hiroko Masuda et al.   BREAST CANCER RESEARCH AND TREATMENT

Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

(2012) A Gallardo et al.   BRITISH JOURNAL OF CANCER

Bcl-2 and BLIMP-1 expression predict worse prognosis in gastric diffuse large B cell lymphoma (DLCBL) while other markers for nodal DLBCL are not useful

(2012) Maialen Martin-Arruti et al.   HISTOPATHOLOGY

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

(2011) G. Somlo et al.   BREAST CANCER RESEARCH AND TREATMENT

Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations

(2011) Ning Lv et al.   Diagnostic Pathology

EGFR expression and gene copy number in triple-negative breast carcinoma

(2010) Berrak Gumuskaya et al.   CANCER GENETICS AND CYTOGENETICS

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   Journal of Oncology Practice

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

(2009) S. Gori et al.   ANNALS OF ONCOLOGY

A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer

(2008) C. L. Arteaga et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER